P-182 Analysis of efficacy and safety of two iron chelators in patients with iron overload (QueLaFer study)

2013 ◽  
Vol 37 ◽  
pp. S105 ◽  
Author(s):  
B. Medrano Engay ◽  
M.P. Irún ◽  
L. Sarría ◽  
M. Andrade ◽  
I. Murillo ◽  
...  
Keyword(s):  
Iron Overload ◽  
Iron Chelators ◽  
Efficacy And Safety

Analysis of efficacy and safety of two iron chelators in type 1 Gaucher disease patients with iron overload

2013 ◽  
Vol 108 (2) ◽  
pp. S64-S65 ◽  
Author(s):  
Blanca Medrano-Engay ◽  
María Pilar Irún ◽  
Luis Sarría ◽  
Pilar Alfonso ◽  
Miguel Pocoví ◽  
...  
Keyword(s):  
Iron Overload ◽  
Gaucher Disease ◽  
Iron Chelators ◽  
Efficacy And Safety ◽  
Type 1 Gaucher Disease

scholarly journals Renal clearable nanochelators for iron overload therapy

2019 ◽  
Vol 10 (1) ◽  
Author(s):  
Homan Kang ◽  
Murui Han ◽  
Jie Xue ◽  
Yoonji Baek ◽  
JuOae Chang ◽  
...  
Keyword(s):  
Iron Overload ◽  
Intravenous Injection ◽  
Renal Excretion ◽  
Fold Increase ◽  
Iron Chelators ◽  
Efficacy And Safety ◽  
Adverse Side Effects ◽  
Pharmacokinetic Properties ◽  
Secondary Iron Overload ◽  
Iron Excretion

Abstract Iron chelators have been widely used to remove excess toxic iron from patients with secondary iron overload. However, small molecule-based iron chelators can cause adverse side effects such as infection, gastrointestinal bleeding, kidney failure, and liver fibrosis. Here we report renal clearable nanochelators for iron overload disorders. First, after a singledose intravenous injection, the nanochelator shows favorable pharmacokinetic properties, such as kidney-specific biodistribution and rapid renal excretion (>80% injected dose in 4 h), compared to native deferoxamine (DFO). Second, subcutaneous (SC) administration of nanochelators improves pharmacodynamics, as evidenced by a 7-fold increase in efficiency of urinary iron excretion compared to intravenous injection. Third, daily SC injections of the nanochelator for 5 days to iron overload mice and rats decrease iron levels in serum and liver. Furthermore, the nanochelator significantly reduces kidney damage caused by iron overload without demonstrating DFO’s own nephrotoxicity. This renal clearable nanochelator provides enhanced efficacy and safety.

Role of vitamin C as an adjuvant therapy to different iron chelators in young β-thalassemia major patients: efficacy and safety in relation to tissue iron overload

2015 ◽  
Vol 96 (3) ◽  
pp. 318-326 ◽  
Author(s):  
Mohsen S. Elalfy ◽  
Maha M. Saber ◽  
Amira Abdel Moneam Adly ◽  
Eman A. Ismail ◽  
Mohamed Tarif ◽  
...  
Keyword(s):  
Adjuvant Therapy ◽  
Vitamin C ◽  
Iron Overload ◽  
Thalassemia Major ◽  
Iron Chelators ◽  
Efficacy And Safety ◽  
Tissue Iron

Therapeutic Macromolecular Iron Chelators

2019 ◽  
Vol 26 (2) ◽  
pp. 323-334 ◽  
Author(s):  
Upendra Bulbake ◽  
Alka Singh ◽  
Abraham J. Domb ◽  
Wahid Khan
Keyword(s):  
Iron Overload ◽  
Chelation Therapy ◽  
Iron Chelator ◽  
Therapeutic Agents ◽  
Iron Chelators ◽  
Low Molecular Weight ◽  
Research Findings ◽  
Pharmaceutical Properties ◽  
Single Living ◽  
Living Process

Iron is a key element for every single living process. On a fundamental level, targeting iron is a valuable approach for the treatment of disorders caused by iron overload. Utilizing iron chelators as therapeutic agents has received expanding consideration in chelation therapy. Approved low molecular weight (MW) iron chelators to treat iron overload may experience short half-lives and toxicities prompting moderately high adverse effects. In recent years, polymeric/macromolecular iron chelators have received attention as therapeutic agents. Polymeric iron chelators show unique pharmaceutical properties that are different to their conventional small molecule counterparts. These polymeric iron chelators possess longer plasma half-lives and reduced toxicities, thus exhibiting a significant supplement to currently using low MW iron chelator therapy. In this review, we have briefly discussed polymeric iron chelators and factors to be considered when designing clinically valuable iron chelators. We have also discussed applications of polymeric iron chelators in the diseases caused by iron overload associated with transfusional hemosiderosis, neurodegenerative disorders, malaria and cancer. With this, research findings for new polymeric iron chelators are also covered.

scholarly journals Treatment of iron overload syndrome: a general review

2019 ◽  
Vol 65 (9) ◽  
pp. 1216-1222 ◽  
Author(s):  
Tadeu Gonçalves de Lima ◽  
Fernanda Luna Neri Benevides ◽  
Flávio Lima Esmeraldo Filho ◽  
Igor Silva Farias ◽  
Diovana Ximenes Cavalcante Dourado ◽  
...  
Keyword(s):  
Life Expectancy ◽  
Oxidative Damage ◽  
Iron Overload ◽  
Hereditary Hemochromatosis ◽  
Treatment Strategies ◽  
Iron Chelators ◽  
Pharmacological Targets ◽  
Pubmed Database ◽  
Toxic Drugs ◽  
Oral Chelators

SUMMARY INTRODUCTION Iron overload is a broad syndrome with a large spectrum of causative etiologies that lead to iron deposition. When iron exceeds defenses, it causes oxidative damage and tissular disfunction. Treatment may prevent organ dysfunction, leading to greater life expectancy. METHODS Literature from the last five years was reviewed through the use of the PubMed database in search of treatment strategies. DISCUSSION Different pharmacological and non-pharmacological strategies are available for the treatment of iron overload and must be used according to etiology and patient compliance. Therapeutic phlebotomy is the basis for the treatment of hereditary hemochromatosis. Transfusional overload patients and those who cannot tolerate phlebotomy need iron chelators. CONCLUSION Advances in the understanding of iron overload have lead to great advances in therapies and new pharmacological targets. Research has lead to better compliance with the use of oral chelators and less toxic drugs.

Design of Polymeric Iron Chelators for Treating Iron Overload in Cooley's Anemia

1982 ◽  
pp. 107-117 ◽  
Author(s):  
ANTHONY WINSTON ◽  
JAMES ROSTHAUSER ◽  
DAVID FAIR ◽  
JAMSHED BAPASOLA ◽  
WEERASAK LERDTHUSNEE
Keyword(s):  
Iron Overload ◽  
Iron Chelators ◽  
Cooley's Anemia

HBED ligand: preclinical studies of a potential alternative to deferoxamine for treatment of chronic iron overload and acute iron poisoning

Blood ◽  
2002 ◽  
Vol 99 (8) ◽  
pp. 3019-3026 ◽  
Author(s):  
Raymond J. Bergeron ◽  
Jan Wiegand ◽  
Gary M. Brittenham
Keyword(s):  
Iron Overload ◽  
Bolus Administration ◽  
Efficacy And Safety ◽  
Diacetic Acid ◽  
Once Daily ◽  
Preclinical Evaluation ◽  
Local Irritation ◽  
Monosodium Salt ◽  
Potential Alternative ◽  
Iron Poisoning

Abstract We have continued the preclinical evaluation of the efficacy and safety of the hexadentate phenolic aminocarboxylate iron chelatorN, N′-bis(2-hydroxybenzyl) ethylenediamine-N, N′-diacetic acid monosodium salt (NaHBED) for the treatment of both chronic transfusional iron overload and acute iron poisoning. We examined the effect of route of administration by giving equimolar amounts of NaHBED and deferoxamine (DFO) to Cebus apella monkeys as either a subcutaneous (SC) bolus or a 20-minute intravenous (IV) infusion. By both routes, NaHBED was consistently about twice as efficient as DFO in producing iron excretion. For both chelators at a dose of 150 μmol/kg, SC was more efficient than IV administration. The biochemical and histopathologic effects of NaHBED administration were assessed. No systemic toxicity was found after either IV administration once daily for 14 days to iron-loaded dogs or after SC administration every other day for 14 days to dogs without iron overload. Evidence of local irritation was found at some SC injection sites. When the NaHBED concentration was reduced to 15% or less in a volume comparable to a clinically useful one, no local irritation was found with SC administration in rats. Because treatment of acute iron poisoning may require rapid chelator infusion, we compared the effects of IV bolus administration of the compounds to normotensive rats. Administration of DFO produced a prompt, prolonged drop in blood pressure and acceleration of heart rate; NaHBED had little effect. NaHBED may provide an alternative to DFO for the treatment of both chronic transfusional iron overload and of acute iron poisoning.

Sign in / Sign up

Export Citation Format

Share Document